
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Michael Anthonavage, VP of innovation at Vitaquest International, about the company’s 2027 consumer trends forecast and how it’s shaping supplement formulation.
The poster references trials on EpiCor that have demonstrated the ingredient’s ability to function as an immune-modulating agent.
Titled “Yeast-Based Fermentate Supplementation Significantly Reduces Inflammation in Two Separate In Vivo Models,” the poster also references three published, double-blind, placebo-controlled randomized trials on EpiCor that have demonstrated the ingredient’s ability to function as an immune-modulating agent by significantly reducing common cold/flu-like and allergic rhinitis symptoms.






